Family Medicine Doctors in Saint Peter, MN Accepting Medicare

9 Family Medicine doctors found. Showing 1 - 9

Kendra Lee Finn, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1901 Old Minnesota Ave, Saint Peter, MN 56082 Phone: 507-625-1811

Elizabeth J Osborne, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1900 Sunrise Dr Ste 200, Saint Peter, MN 56082 Phone: 507-931-2110

Mohammed Solaiman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1900 Sunrise Dr Ste 200, Saint Peter, MN 56082 Phone: 507-931-2110

Charles Rodney Butler Iii, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 100 Freeman Dr, Saint Peter, MN 56082 Phone: 507-931-7125    Fax: 507-931-7126

Dr. Kae B Loverink, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1900 Sunrise Dr, Saint Peter, MN 56082 Phone: 507-934-7312    Fax: 507-934-8516

Amy A Kvidera, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 618 N 9th St, Saint Peter, MN 56082 Phone: 507-934-1211

Kimberly Jean Beecher, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1900 Sunrise Dr, Suite 200, Saint Peter, MN 56082 Phone: 507-931-2110

Nadia Malik, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1900 Sunrise Dr, Mayo Clinic Health System, Saint Peter, MN 56082 Phone: 507-931-2110

Mark S Akland, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1900 Sunrise Dr Ste 200, Saint Peter, MN 56082 Phone: 507-931-2110

News Archive

Unique antiviral action of cholesterol 25-hydroxylase against SARS-CoV-2

A new study by U.S. and Chinese researchers, currently available on the bioRxiv* preprint server, demonstrates how cholesterol 25-hydroxylase and its enzymatic product 25-hydroxycholesterol can inhibit membrane fus

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).

Study suggests unexpected role for NLRP3 protein in cancer vaccine development

The promise of vaccines targeted against various types of cancer has raised the hopes of patients and their families. The reality, however, is that these promising treatments are difficult to develop. One of the challenges is identifying a discrete cellular target to stop cancer growth without inactivating the immune system. Scientists at UNC Lineberger Comprehensive Cancer Center report a laboratory finding that has the potential to increase the effectiveness of therapeutic cancer vaccines.

Study may help guide patients and physicians to determine appropriate treatment option for early breast cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age. It was also the most expensive treatment option in a younger patient population, according to a new study from The University of Texas MD Anderson Cancer Center.

New approach to combination drug design could be applied to disease therapies beyond diabetes

Biomedical engineers at Duke University have shown that the efficacy of a two-pronged type 2 diabetes treatment increases when the drugs are linked by a heat-sensitive tether rather than simply concurrently administered.

Read more Medical News

› Verified 2 days ago